TFPI or uPA-PAI-1 complex affect cell function through expression variation of type II very low density lipoprotein receptor

FEBS Letters

Volumn 584, Issue 15, 2010, Pages 3469-3473

  Di, Yong ^a   Liu, Zhiguo ^b   Tian, Jun ^a   Zong, Yiqiang ^a   Yang, Pu ^a,c   Qu, Shen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN POLYTECHNIC UNIVERSITY   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Catenin; Subtype; TFPI; UPA PAI 1; VLDLR

Indexed keywords

BETA CATENIN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN RECEPTOR 1; VERY LOW DENSITY LIPOPROTEIN RECEPTOR 2;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIPOPROTEINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, LDL; RNA, MESSENGER; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77955267857     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.07.005     Document Type: Article

References (21)

1. Iijima H., Miyazawa M., Sakai J., Magoori K., Ito M.R., Suzuki H., Nose M., Kawarabayasi Y., Yamamoto T.T. Expression and characterization of a very low density lipoprotein receptor variant lacking the O-link sugar region generated by alternative splicing. J. Biochem. 1998, 124:747-755.
2. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Proc. Natl. Acad. Sci. USA 1992, 89:9252-9256.
3. Webb J.C., Patel D.D., Jones M.D., Knight B.L., Soutar A.K. Characterization and tissue-specific expression of the 'human very low density lipoprotein (VLDL) receptor' mRNA. Hum. Mol. Genet. 1994, 3:531-537.
4. Nakamura Y., Yamatomo M., Kumamaru E. Very low-density lipoprotein receptor in fetal intestine and gastric adenocarcinoma cells. Arch. Pathol. Lab. Med. 2000, 124:119-122.
5. Chen T., Wu F., Chen F.M., Tian J., Qu S. Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations. World J. Gastroenterol. 2005, 11:2817-2821.
6. Wada Y., Homma Y., Nakazato K., Ishibashi T., Maruyama Y. Effect of overexpression of very low density lipoprotein receptor on cell growth. Heart Vessels 2000, 15:74-80.
7. Yang P., Liu Z.G., Wang H.X., Tian J., Li Y.H., Zong Y.Q., Qu S. Enhanced activity of very low density lipoprotein receptor II promotes SGC7901 cell proliferation and migration. Life Sci. 2009, 84:402-408.
8. Nykjaer A., Willnow T.E. The low-density lipoprotein receptor gene family: a cellular Swiss army knife?. Trends Cell Biol. 2002, 12:273-280.
9. Hembrough T.A., Ruiz J.F., Papathanassiu A.E., Green S.J., Strickland D.K. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J. Biol. Chem. 2001, 276:12241-12248.
10. Hirotani-Ikejima H., Kokame K., Hamuro T., Bu G., Kato H., Miyata T. Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem. Biophys. Res. Commun. 2002, 299:847-852.
11. Webb D.J., Nguyen D.H., Sankovie M., Gonias S.L. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer motility in vitro. J. Biol. Chem. 1999, 274:7412-7420.
12. Webb D.J., Thomas K.S., Gonias S.L. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J. Cell Biol. 2001, 152:741-752.
13. Herz J., Kowal R.C., Ho Y.K., Brown M.S., Goldstein J.L. Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver. J. Biol. Chem. 1990, 265:21355-21362.
14. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 2003, 200:448-464.
15. Kiaris H., Chatzistamou I., Schally A.V., Halmos G., Varga J.L., Koutslini H., Kalofoutis A. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc. Natl. Acad. Sci. USA 2003, 100:9512-9517.
16. Mehta K.D., Miller L. Inhibition of stress-activated p38 mitogen-activated protein kinase induces low-density lipoprotein receptor expression. Trends Cardiovasc. Med. 1999, 9:201-205.
17. Kreuter R., Soutar A.K., Wade D.P. Transcription factors CCAAT/enhancer-binding protein β and nuclear factor-Y bind to discrete regulatory elements in the very low density lipoprotein receptor promoter. J. Lipid Res. 1999, 40:376-386.
18. Hsien-Yeh H., Yuh-Ching T. Tumor necrosis factor-a-mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage. J. Biol. Chem. 2000, 275:41035-41048.
19. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., Bartholomeusz G., Li Y., Pan Y., Li Z., Bargou R.C., Qin J., Lai C.C., Tsai F.J., Tsai C.H., Hung M.C. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 2005, 19:159-170.
20. Qin X., Zhang H., Zhou X., Wang C., Zhang H., Zhang X., Ye L. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl. Res. 2007, 150:281-294.
21. Luu H.H., Zhang R., Haydon R.C., Rayburn E., Kang Q., Si W., Park J.K., Wang H., Peng Y., Jiang W., He T.C. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets 2004, 4:653-671.